A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party.
暂无分享，去创建一个
M. Parmar | P. Clark | G. Griffiths | S. Harland | G. Mead | P. Harper | M. Parmar | J. Roberts | J. Roberts | P. Harper | M. Russell | R. Cowan | B. Uscinska | S. Harland | O. B. O. K. R. D. W. Party | B. Uscinska | Godfrey G. Griffiths
[1] I. Tannock,et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. , 1989, The Journal of urology.
[2] N. Geller,et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. , 1988, The Journal of urology.
[3] F. Freiha,et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] N. Geller,et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. , 1985, The Journal of urology.
[5] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .